# US 2014/0155430 A1 · Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155430 A1
- Document ID: US20140155430A1
- Status: Published application
- Kind: A1
- Application number: 14/175,654
- Filed: 2014-02-07
- Published: 2014-06-05
- Earliest claimed: 2008-11-19
- Assignees: EnVivo Pharmaceuticals, Inc.
- Applicants: EnVivo Pharmaceuticals, Inc.
- Inventors: Richard Chesworth; Gideon Shapiro; Gerhard Koenig
- Web page: https://patentgrep.com/patent/US20140155430A1

## CPC

- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses to improve cognition.

## Claims

### Claim 1

A method of treating negative symptoms associated with Schizophrenia in a patient in need thereof, comprising:
administering to said patient a daily dose in the range of between 0.1 mg to 3.0 mg of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable salt of the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide is: (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride; (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate; or (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride solvate.

### Claim 3 (depends on 2)

The method of claim 2, wherein the pharmaceutically acceptable salt of the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide is administered to the patient.

### Claim 4 (depends on 3)

The method of claim 3, wherein the pharmaceutically acceptable salt of the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide is (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride.

### Claim 5 (depends on 3)

The method of claim 3, wherein the pharmaceutically acceptable salt of the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide is (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate.

### Claim 6 (depends on 5)

The method of claim 5, wherein the daily dose is in the range of between 0.3 mg to 1.5 mg.

### Claim 7 (depends on 5)

The method of claim 5, wherein the daily dose is in the range of between 0.7 mg to 1.25 mg.

### Claim 8 (depends on 5)

The method of claim 5, wherein the daily dose is in the range of between 1.0 mg to 3.0 mg.

### Claim 9 (depends on 5)

The method of claim 5, wherein the daily dose is in the range of between 1.5 mg to 2.5 mg.

### Claim 10 (depends on 5)

The method of claim 5, wherein the daily dose is in the range of between 1.75 mg to 2.25 mg.

### Claim 11 (depends on 5)

The method of claim 5, wherein the daily dose is in the range of between 2.0 mg to 3.0 mg.

### Claim 12 (depends on 1)

The method of claim 1, wherein the schizophrenia comprises a paranoid type, a disorganized type, catatonic type, or an undifferentiated type.

### Claim 13 (depends on 1)

The method of claim 1, wherein the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition.